Hyperbaric Oxygen Therapy and Healthy Aging
Hyperbaric oxygen therapy (HBOT) exposes a person to oxygen at pressures above normal atmospheric pressure inside a pressurized chamber. This sharply increases the amount of dissolved oxygen carried in plasma and raises tissue oxygen tension. HBOT has established medical uses in conditions such as decompression sickness, carbon-monoxide poisoning, selected non-healing wounds and certain radiation injuries. Interest in aging research comes from the possibility that repeated, controlled changes in tissue oxygenation may trigger adaptive responses that influence vascular function, inflammation and cellular stress resistance.
Oxygen, oxidative stress and hormesis. Oxygen is indispensable for mitochondrial energy production, but excessive oxygen exposure can also increase reactive oxygen species. HBOT therefore produces a paradox: each session creates a transient hyperoxic stimulus, yet repeated sessions may induce compensatory antioxidant and stress-response pathways. Experimental work has described changes in HIF-1 signaling, SIRT1, endogenous antioxidant enzymes and pathways involved in mitochondrial adaptation. This phenomenon is sometimes described as a hyperoxic-hypoxic paradox because repeated fluctuations in oxygen availability can activate signaling normally associated with hypoxia despite the high-oxygen environment during treatment.
Vascular biology. One of the most plausible systemic effects of HBOT is improved oxygen delivery to hypoxic tissue together with stimulation of angiogenic and repair pathways. Repeated treatment can alter endothelial signaling, nitric-oxide biology and expression of vascular growth factors. In chronic wound care these mechanisms are clinically relevant because oxygen availability strongly affects collagen synthesis, immune function and tissue repair. Aging research asks whether similar vascular effects can improve perfusion in otherwise healthy older adults, but the evidence for this broader use is much less mature.
Inflammation and cellular repair. Animal studies report modulation of inflammatory cytokines such as TNF-α and IL-6 after repeated HBOT. Experimental work also suggests effects on AMPK, mTOR and autophagy, with increased expression of proteins involved in clearance of damaged organelles and aggregated proteins. These findings provide a mechanistic link between intermittent hyperoxia and pathways often studied in geroscience, but most remain preclinical.
Telomeres and senescent cells. A widely discussed prospective study in adults over 64 used a protocol of 60 HBOT sessions and reported increases in telomere length in several circulating immune-cell populations together with reductions in some senescent T-cell subsets. The reported changes were unusually large for a short intervention and generated substantial interest. They should nevertheless be interpreted cautiously: the study was relatively small, did not establish that the telomere measurements represented systemic rejuvenation, and did not show that the intervention extended lifespan or prevented age-related disease.
Cognition and brain function. HBOT has been investigated in older adults and in neurological conditions because elevated tissue oxygenation can influence cerebral blood flow, neuroplasticity and mitochondrial function. Small studies have reported improvements in selected cognitive domains, cerebral perfusion or quality-of-life measures after repeated treatment. Animal experiments have also reported better learning and memory together with changes in autophagy and oxidative-stress markers. The clinical importance of these findings remains uncertain because protocols, populations and outcome measures vary considerably.
Bone and musculoskeletal aging. In aged or experimentally aged rodents, HBOT has altered inflammatory and oxidative markers in bone and in some studies improved bone microarchitecture. Because bone remodeling depends on vascular supply, osteoblast activity and inflammatory balance, the mechanism is plausible. Human evidence for osteoporosis prevention or general musculoskeletal rejuvenation is still limited.
Safety. HBOT is a medical procedure rather than a simple wellness exposure. The most common adverse effects are pressure-related ear or sinus injury and temporary visual changes. Oxygen toxicity can cause pulmonary irritation and, rarely, seizures. Claustrophobia may also limit treatment. Risks increase with inappropriate pressure, session duration or patient selection. The therapy also has specific contraindications and interactions that require medical screening.
What is established and what is not. HBOT is well established for a defined group of medical indications in which enhanced oxygen delivery has a clear therapeutic rationale. By contrast, using repeated HBOT to slow normal aging remains investigational. Small human studies on cognition, perfusion, telomeres and senescent-cell markers are intriguing but do not yet demonstrate reduced mortality, delayed multimorbidity or extended human lifespan.
Overall, hyperbaric oxygen therapy is biologically capable of altering tissue oxygenation, vascular signaling, oxidative-stress responses and cellular repair pathways. These effects make it an interesting geroscience intervention, but the leap from biomarker changes to meaningful extension of healthspan has not yet been established.